Article citationsMore>>

Kim, Y.-J., Lim, K.-H., Kim, M.-Y., Jo, E.-J., Lee, S.-Y., Lee, S.-E., et al. (2014) Cross-Reactivity to Acetaminophen and Celecoxib According to the Type of Nonsteroidal Anti-Inflammatory Drug Hypersensitivity. Allergy, Asthma & Immunology Research, 6, 156-162.
https://doi.org/10.4168/aair.2014.6.2.156

has been cited by the following article:

• TITLE: Oral Provocation Test in Non-Steroidal Anti-Inflammatory Drug Hypersensitive Patients Referred to Singapore General Hospital

  AUTHORS: Chaw Su Naing, Yong Yeow Chong

  KEYWORDS: Non-Steroidal, Anti-Inflammatory Drugs, Hypersensitivity, Cyclooxygenase 2

  JOURNAL NAME: Open Access Library Journal, Vol.4 No.3, March 28, 2017

  ABSTRACT: Introduction: Non-steroidal anti-inflammatory drugs (NSAIDs) are frequently prescribed classes of drugs and are easily accessible as over-the-counter anti-inflammatory drugs in Singapore. NSAIDs hypersensitivity is the second most common referral to allergy clinic in a tertiary referral centre. Methods: Referred patients with history of NSAID intolerance were underwent open challenge with 1) putative NSAID to confirm the diagnosis; 2) Aspirin to determine the cross-reactivity or 3) selective cyclooxygenase-2 (COX-2) inhibitor to identify the suitable alternative. Data were analysed retrospectively. Results: Over a 4-year period (2010-2014), a total of 127 patients (mean age SD 40.7 /- 15.2) underwent a total of 155 open-labelled labelled NSAIDs oral provocation tests (OPT). Overall positive challenge rate is 26.5% (41 out of 155). Despite having a clinical relevant history of causative, only 29.4% (20 out of 68) had positive OPT to putative NSAIDs. Using selective COX-2 inhibitor challenge for assessing the tolerability of suitable alternative, we found only 8.8% (5 out of 57) positive challenge. Conclusions: In our 4-year patients cohort with history of NSAIDs of intolerance, positive OPT rate of 26.5% in confirming diagnosis of NSAIDs hypersensitivity. The intolerance to selective COX-2 inhibitor was found in 8.8% of patients with non-steroidal anti-inflammatory drugs hypersensitivity patients.